Op-P (Emotional Health Booster)
Brand Names: Op-P
Methodology & AI Transparency ⓘ
Op-P (Emotional Health Booster) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active pharmaceutical ingredient Emotional Health Booster and registered by Vitality Works, Inc., Op-P operates as a over-the-counter branded non-standardized plant allergenic extract therapy (RxNorm RXN-B64616100; NDC 64616-100).
- 2 Real-world patient consensus: Commercial Op-P monograph (8 [hp_X]/mL / 12 [hp_X]/mL Liquid) cross-indexed with generic Emotional Health Booster for therapeutic equivalence review.
- 3 Typical cash cost range: Dispensing cost comparison spans $104.26 mail/discount cash up to $276.29 uninsured retail (federal NADAC $1.3300).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Op-P (Emotional Health Booster): arthralgia (5.9%), restlessness (5.3%), nausea (8.2%).
Ask our AI Specialists anything about Op-P (Emotional Health Booster)
Op-P (Emotional Health Booster) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active pharmaceutical ingredient Emotional Health Booster and registered by Vitality Works, Inc., Op-P operates as a over-the-counter branded non-standardized plant allergenic extract therapy (RxNorm RXN-B64616100; NDC 64616-100). Under 2025-12-17 FDA labeling for 8 [hp_X]/mL / 12 [hp_X]/mL Liquid; Therapeutic monitoring titration for Op-P (Emotional Health Booster) (non-standardized plant allergenic extract), OP-P For the temporary relief of general anxiety, sleeplessness, depression, muscle and joint pain and digestive discomfort
Bioactive Emotional Health Booster within Op-P governs non-standardized plant allergenic extract target modulation with class-characteristic hepatorenal disposition. Commercialized across 8 [hp_X]/mL / 12 [hp_X]/mL Liquid; Therapeutic monitoring titration for Op-P (Emotional Health Booster) (non-standardized plant allergenic extract) (registered by Vitality Works, Inc., SPL 2025-12-17), Op-P combines branded dosage-form consistency (NDC 64616-100) with transparent cash-pay comparisons spanning $104.26 to $276.29.
Clinical clearance of Op-P (Emotional Health Booster) (Non-Standardized Plant Allergenic Extract) relies on dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of op-p (emotional health booster) with a Mean elimination half-life of 10 to 17 hours across adult Op-P (Emotional Health Booster) dosing half-life; patients absorbing at Oral fraction absorbed ranges from 75% to 87% (Op-P (Emotional Health Booster) 8) bioavailability typically observe target onset around oral tmax achieved within 2 to 4 hours following op-p (emotional health booster) ingestion.
FDA clinical labeling for Op-P (Emotional Health Booster) restricts administration in previous anaphylactoid or exfoliative reaction attributed to op-p (emotional health booster); clinical scenarios where non-standardized plant allergenic extract exposure from op-p (emotional health booster) poses unacceptable risk across 8 [hp_X]/mL / 12 [hp_X]/mL Liquid, Therapeutic monitoring titration for Op-P (Emotional Health Booster) (non-standardized plant allergenic extract), with self-reported patient tracking dominated by nausea (8.2% of reports), headache (8% of reports), dizziness (6.6% of reports).
Verify medication reconciliation lists so Op-P (Emotional Health Booster) is not inadvertently duplicated with another non-standardized plant allergenic extract.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Op-P (Emotional Health Booster) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Op-P (Emotional Health Booster)
- Clinical scenarios where non-standardized plant allergenic extract exposure from Op-P (Emotional Health Booster) poses unacceptable risk
Logged Side-Effect Incidence (18 Reports)
Op-P (Emotional Health Booster) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Op-P (Emotional Health Booster))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Emotional changes in men treated with sildenafil citrate for erectile: What a 841-Participant Study Found The physiologic and emotional benefits of sildenafil in the treatment of ED were confirmed, overall and in men with comorbid high blood pressure, high cholesterol, benign prostatic hypertrophy, and/or depression. The journal of sexual medicine • 2009-12-15 • Randomized Controlled Trial | N = 841 | 93/100 | PMID 19796051 ↗ |
| Can This Approach Help? Inside the Latest Research on Acute neurofunctional effects of escitalopram during emotional processing in Furthermore, pretreatment and early-treatment amygdala connectivity could serve as biomarkers of SSRI treatment response in adolescents with GAD. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology • 2022-04-15 • Randomized Controlled Trial | N = 36 | 88/100 | PMID 34580419 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Among 126 participants who were randomized (mean [SD] age, 55.3 years [14.9 years]; 78 women [61.9%]), 114 (90.5%) completed the trial. JAMA • 2019-08-20 • Randomized Controlled Trial | N = 64 | 88/100 | PMID 31429896 ↗ |
| Can This Approach Help? Inside the Latest Research on A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release DR/ER-MPH treatment resulted in statistically significant improvements in EL to the level of non-ADHD peers as contextualized by T -scores. Journal of attention disorders • 2024-06-15 • Phase III Randomized Trial | N = 117 | 88/100 | PMID 38600754 ↗ |
| Can This Approach Help? Inside the Latest Research on Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Despite large improvements in depressive symptoms in the psilocybin group, psilocybin therapy had only a minor effect on brain responsiveness to emotional stimuli. The American journal of psychiatry • 2025-06-01 • Randomized Controlled Trial | N = 25 | 88/100 | PMID 40329640 ↗ |
Op-P (Emotional Health Booster) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.3300/unit (~$39.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $276.29 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $104.26 / mo | View logs ↓ |
Op-P (Emotional Health Booster) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Op-P (Emotional Health Booster) RxNorm Concept ID | RXN-B64616100 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.3300 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $276.29 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $104.26 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Op-P (Emotional Health Booster) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Op-P (Emotional Health Booster) (non-standardized plant allergenic extract) monograph synthesizing RxNorm RXN-B64616100, openFDA FAERS signals, and $104.26–$276.29 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Op-P (Emotional Health Booster) community threads and patient logs by age, biological sex, dosage, and treatment duration.